Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $16.00 Consensus Target Price from Brokerages

Tenax Therapeutics, Inc. (NASDAQ:TENX) has earned an average recommendation of “Buy” from the five ratings firms that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $16.00.

TENX has been the subject of several research reports. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. William Blair assumed coverage on shares of Tenax Therapeutics in a research note on Monday, September 30th. They set an “outperform” rating for the company. StockNews.com initiated coverage on Tenax Therapeutics in a research note on Thursday, September 26th. They issued a “sell” rating on the stock. Guggenheim started coverage on Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Leerink Partners began coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 target price on the stock.

Institutional Investors Weigh In On Tenax Therapeutics

Hedge funds have recently modified their holdings of the business. Sphera Funds Management LTD. bought a new position in Tenax Therapeutics in the 3rd quarter worth $101,000. Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics in the third quarter worth about $173,000. Finally, Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics in the third quarter worth about $288,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Trading Up 1.4 %

NASDAQ TENX opened at $4.92 on Tuesday. The stock has a 50-day moving average of $4.11 and a 200 day moving average of $3.73. Tenax Therapeutics has a one year low of $2.77 and a one year high of $33.44.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.